Reta and Bypass

No, I don't know of any people on Retatrutide who are post-op Coronary Arterial Bypass Graft Surgery. but your interesting question led me to find a retrospective study of 820 post-CABG patients and GLP1 receptor agonists. https://www.cureus.com/articles/425...bg-in-adults-with-congenital-heart-disease#!/

The results: "In adult CHD patients undergoing CABG, perioperative use of GLP-1 receptor agonists was associated with a significant reduction in one-year hospital readmission rates, without increased risk of mortality, postoperative complications, or known GLP-1-related adverse events."
 
Good-Heart6425 said:


No, I don't know of any people on Retatrutide who are post-op Coronary Arterial Bypass Graft Surgery. but your interesting question led me to find a retrospective study of 820 post-CABG patients and GLP1 receptor agonists. https://www.cureus.com/articles/425...bg-in-adults-with-congenital-heart-disease#!/

The results: "In adult CHD patients undergoing CABG, perioperative use of GLP-1 receptor agonists was associated with a significant reduction in one-year hospital readmission rates, without increased risk of mortality, postoperative complications, or known GLP-1-related adverse events."

Click to expand...
Click to expand...
I found the same info on Gemini but the increase in RHR due to glucagon with the reta is my only real concern. It's for my dad, he's 6months post op and recovered great but he's put on a little weight and his blood test numbers were just a bit high out of spec. Doc mentioned glp1/2 would be okay but stay away from retatrutide (because there is no such thing as "retatrutide (because there is no such thing as "GLP-3")"). Doc used those terms which is hilarious to me but I explained it to my dad.
 
MakeNoPeaceWithEvil said:


I found the same info on Gemini but the increase in RHR due to glucagon with the reta is my only real concern. It's for my dad, he's 6months post op and recovered great but he's put on a little weight and his blood test numbers were just a bit high out of spec. Doc mentioned glp1/2 would be okay but stay away from retatrutide (because there is no such thing as "retatrutide (because there is no such thing as "retatrutide (because there is no such thing as "GLP-3")")"). Doc used those terms which is hilarious to me but I explained it to my dad.

Click to expand...
Click to expand...
Yr Dad's doc's idea is evidence based. . see



March 3, 2026 you are here: science media centre > roundups for journalists > expert reaction to study in rodent cells looking at how the GLP-1 peptide might impact measures of heart vessel damage

A study in rodent cells published in Nature Communications looks at GLP-1 peptides and heart vessel damage. Prof Bryan Williams, Chief Scientific and Medical Officer, BHF (British Heart Foundation), said: “Restoring blood flow to the heart muscle is a major objective of heart attack treatment, not just through opening up the major arteries supplying the heart, but also restoring blood flow through the smaller microvessels that supply the heart muscle.

“This research suggests that mimicking the action of the GLP‑1 hormone may have potential to improve blood flow through microvessels and perhaps one day could have a role in heart attack treatment. This will require detailed studies in humans and clinical trials first.

“Large clinical trials of GLP‑1 medicines, such as Ozempic and Wegovy, have shown benefits on heart health beyond weight loss. But how they produce these effects has remained unclear. This fascinating study offers one possible explanation, suggesting that they may help to improve blood flow through the heart’s smallest blood vessels.”





‘GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection’ by Svetlana Mastitskaya et al. was published in Nature Communications at 00:01 UK time on Tuesday 3 March 2026.



DOI: 10.1038/s41467-026-69555-1





Declared interests

No declaration received for Prof Bryan Williams specifically.

For the BHF: “Dr Svetlana Mastitskaya has a BHF Research Fellowship, which helped to support this study. David Attwell (senior author) is Director of the BHF-UK DRI Centre for Vascular Dementia Research.”
 
I have known , non occlusive coronary artery disease from angiography but very high coronary calcium score, no bypasses thankfully. Taking reta 5mg with tirz 15mg. My best guess is any added risks from high dose/combo GLP therapy is lower than the risks of regaining the 80 kg I have lost.

Both semaglutide and tirzepatide have been shown to improve outcomes in persons with known cardiovascular disease, lower risk of death, heart attack, stroke, less well proven for heart failure, but some aspects improved.

Reta does not have that data yet. And it increases heart rate more than the other GLP's.

If there was a history of arrythmias I would avoid reta. Tirz is a safer choice than reta at this point, it has not been established that the heart rate increase does not cause problems, and tirz has been proven to benefit heart disease, and reta has not. Reta is fairly likely to end up having that evidence in a few years time, but there is a chance it will make arrythmias more likely.

Someone who has had bypass surgery may or may not have occlusive disease, mainly depending on how long ago it was done. If recently then the added possible risks of reta are probably low, if a decade ago , the added risks might be more of an issue, but either way unless there is a very good reason to choose reta, tirz is safer.
 
MakeNoPeaceWithEvil said:


Yo, forum reply changed my post wording??

Click to expand...
Click to expand...
Search results for query: retatrutide (because there is no such thing as "retatrutide (because there is no such thing as "GLP-3")")

you know, I do love the Easter chicken embryos, but I swear to God sometimes it's like trying to talk over a rubber chicken FIGHT.
 
Back
Top